Research programme: rheumatoid arthritis gene therapy - Introgen/University of California
Alternative Names: Rheumatoid arthritis gene therapy - Introgen/University of CaliforniaLatest Information Update: 28 Sep 2006
At a glance
- Originator Introgen Therapeutics
- Developer Introgen Therapeutics; University of California, San Diego
- Class Antirheumatics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 28 Sep 2006 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 13 Jun 2001 Preclinical development for Rheumatoid arthritis in USA (Unknown route)